<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Specific Immune Response - Medical Microbiology</title>
    
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <!-- KaTeX for Math rendering -->
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.9/dist/katex.min.css">
    <script defer src="https://cdn.jsdelivr.net/npm/katex@0.16.9/dist/katex.min.js"></script>
    <script defer src="https://cdn.jsdelivr.net/npm/katex@0.16.9/dist/contrib/auto-render.min.js" onload="renderMathInElement(document.body, {
        delimiters: [
            {left: '$$', right: '$$', display: true},
            {left: '$', right: '$', display: false}
        ]
    });"></script>
    
    <link rel="stylesheet" href="../styles/main.css">
</head>
<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                
                <!-- TOP NAVIGATION -->
                <nav class="document-nav" role="navigation" aria-label="Document Navigation">
                    <div class="nav-links">
                        <a href="topic-02-antigen-antibody.html" class="nav-button nav-button--previous">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Previous</span>
                        </a>
                        
                        <a href="../index.html" class="nav-button">
                            <span class="nav-icon">üè†</span>
                            <span class="nav-text">Home</span>
                        </a>
                        
                        <a href="topic-04-in-vitro-reactions.html" class="nav-button nav-button--next">
                            <span class="nav-text">Next</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                    <div class="document-progress">
                        <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 60%;"></div>
                        </div>
                        <span class="progress-text">Topic 3 of 5</span>
                    </div>
                </nav>

                <header class="document-header">
                    <div class="header-badge">
                        <span>üõ°Ô∏è</span>
                        <span>Topic 03</span>
                    </div>
                    <h1 class="document-title">Specific Immune Response</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Basic Immunology and Serodiagnosis</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>30 min read</span>
                        </div>
                    </div>
                </header>

                <main id="main-content" class="content-wrapper">
                    
                    <p>Specific immune response can be either antibody mediated or cell mediated.</p>

                    <!-- Section 1: Antibody Mediated Immune Response -->
                    <section class="content-section" id="ami">
                        <div class="section-header">
                            <div class="section-number">01</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß¨</span>
                                Antibody Mediated Immune Response
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Specific antibody mediated immune response is also referred to as humoral immune response. The cells responsible for the synthesis of antibody molecules are B-lymphocytes. Each immunocompetent B-lymphocyte has an immunoglobulin of appropriately coded specificity on its surface, before its exposure to the antigen. The specificity of the antibody molecule for a particular antigen is determined at the level of the gene.</p>
                            <p>The undifferentiated stem cell has a set of genes capable of coding for 10^6 to 10^8 different types of antibody molecules. These immunoglobulin genes occur on widely separated fragments of DNA. For example, the set of genes for heavy (H) chain coding are separate from those coding for light (L) chains.</p>

                            <h3>Activation of B-lymphocytes</h3>
                            <p>Activation of B-lymphocytes by an antigen can be either dependent or independent of T-cells, which, in turn, depends on the nature of the antigen.</p>

                            <div class="callout callout--info">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ö°</span>
                                    <h4 class="callout-title">T-cell Independent activation</h4>
                                </div>
                                <div class="callout-content">
                                    <p>Antigens that are made up of large polymers with repeating identical subunits can directly induce B-lymphocytes to produce specific antibodies. Such antigens have many antigenic determinants or epitopes and are capable of stimulating many clones of B-lymphocytes. These are called polyclonal activators, e.g. lipopolysaccharide.</p>
                                    <p>The subunits of the antigen bind to the binding sites on the specific surface immunoglobulin molecules on B-lymphocytes. This stimulates the B-lymphocytes to proliferate into a clone of identical cells. They subsequently mature into plasma cells which produce and secrete antibody molecules into the body fluids. The T-cell independent antibody response has three characteristic features:</p>
                                    <ol class="enhanced-list">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">(i) It can produce only IgM antibody.</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">(ii) Help from T-helper (Th) cell is not required.</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">(iii) There is no memory of the antibody response.</span></li>
                                    </ol>
                                </div>
                            </div>

                            <div class="callout callout--note">
                                <div class="callout-header">
                                    <span class="callout-icon">ü§ù</span>
                                    <h4 class="callout-title">T-cell dependent activation</h4>
                                </div>
                                <div class="callout-content">
                                    <p>This is the mechanism by which most of the antigens stimulate production of antibodies. The characteristics of this type of response are:</p>
                                    <ol class="enhanced-list">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">(i) It can produce antibody of any immunoglobulin class.</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">(ii) It depends on the help from T-helper (Th) lymphocytes.</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">(iii) The antibody response also results in the induction of 'memory'.</span></li>
                                    </ol>
                                </div>
                            </div>
                        </div>
                    </section>

                    <!-- Section 2: Mechanism of AMI -->
                    <section class="content-section" id="mechanism-ami">
                        <div class="section-header">
                            <div class="section-number">02</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚öôÔ∏è</span>
                                Mechanism of Antibody Mediated Immunity (AMI)
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>This mechanism can be briefly explained as follows:</p>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(i) When an antigen comes in contact with a macrophage, it is phagocytosed.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(ii) Within the macrophage, the enzymes partially degrade the antigen in such a way that the antigenic determinants are exposed.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(iii) This partially degraded antigen is then placed on the surface of the macrophage next to the HLA-D or Ia marker, which is a genetically determined Class II antigen of the HLA system.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(iv) The T-helper (Th) cells have a specific T-cell receptor (TcR), specific for each antigen, on their surface in association with the CD3 (Cluster of Differentiation 3) molecule. When such 'resting' or non-activated Th cells come in contact with the macrophage with the antigen-Ia complex on its surface, these two complexes bind with each other (Fig. 3.1).</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">
                                        (v) At this stage, the resting Th cell is activated by a monokine (Interleukin-1, IL-1) produced by the macrophage. The activated Th undergoes a series of biochemical changes resulting in self stimulatory response by:
                                        <br>(a) production of large quantities of lymphokines, including interleukin-2 (IL-2).
                                        <br>(b) acquiring surface membrane receptors for IL-2.
                                    </span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(vi) Binding of IL-2 to its receptor on the activated Th leads to the proliferation of Th to produce a clone of identical Th cells specific for the inducing antigen. Thus the response is amplified at this stage.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(vi) The activated Th cells also produce Interleukins 4, 5 and 6 (IL-4, IL-5 and IL-6) among other lymphokines, which participate later in B-cell proliferation and differentiation.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">
                                        (vii) B-lymphocytes can come in contact with the antigen in three different ways:
                                        <br>(a) Direct binding of the antigen to the specific surface Ig molecule on the B-cell.
                                        <br>(b) Presentation of the antigen by an activated Th cell to B-cell.
                                        <br>(c) Presentation of the antigen by macrophages or other B-cells possessing bound antigen on their surface.
                                    </span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(ix) At this stage, only those antigens capable of initiating B-cell proliferation without the influence of Th cells can induce antibody production independently. All other antigens can induce proliferation of B-cells into a clone of identical cells only under the influence of IL-4 and IL-5, released by Th.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(x) After proliferation of B-cells, IL-5 and IL-6 produced by activated Th trigger differentiation of B-cells into plasma cells to secret antibody molecules specific for the inducing antigen (Fig. 3.1).</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(xi) Instead of differentiating into plasma cells, some of the stimulated B-cells develop into mature memory cells with very long life. These can be activated rapidly upon subsequent exposure to the same antigen.</span>
                                </li>
                            </ol>

                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../assets/images/image-20251219-e2953ff8.jpeg" alt="T-cell dependant activation of B-lymphocytes" class="figure-image">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Fig. 3.1 T-cell dependant activation of B-lymphocytes</figcaption>
                            </figure>

                            <h3>Primary Antibody Response</h3>
                            <p>When an individual is exposed to an antigen for the first time, it results in the primary antibody response. Characteristically, in the primary response, there is a lag period before any antibody is produced. This is due to the time required for the activation of B-cells after the first exposure to the antigen. This lag period depends on the type and dose of antigen, its route of entry, as well as host related factors. Generally, the lag period is for three-four days before detectable levels of antibody appear. The first immunoglobulin to be produced is IgM, which rises to a peak in one to ten weeks, then starts dropping below detectable levels over the next few weeks (Fig. 3.2).</p>
                            <p>The production of IgG is slower, and begins about one to two weeks after exposure, reaches a peak within a few weeks and gradually decreases over the next few months. Some IgG antibodies may be present in the body for years.</p>

                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../assets/images/image-20251219-08380b27.jpeg" alt="Primary (first dose) and secondary (second dose) antibody response to antigen" class="figure-image">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Fig. 3.2 Primary (first dose) and secondary (second dose) antibody response to antigen</figcaption>
                            </figure>
                        </div>
                    </section>

                    <!-- Section 3: CMI & Cytokines -->
                    <section class="content-section" id="cmi">
                        <div class="section-header">
                            <div class="section-number">03</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü¶†</span>
                                Cell Mediated Immune Response (CMI)
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>CMI is another type of specific immune response and does not involve antibody. This is an important group of responses mediated by T-lymphocytes, in which B-lymphocytes do not play any role. CMI was originally identified by its role in immunity to tuberculosis and viral infections. It was also found to be involved in graft rejection, chronic inflammation, tumour immunity, and in delayed type hypersensitivity.</p>
                            <p>CMI is regulated by many suppressor cells and factors which are able to limit the damaging effect of CMI. However, in some diseases, this regulatory activity can impair the protective aspect of the system.</p>

                            <h3>Cytokines</h3>
                            <p>The process of cell mediated immunity (CMI) is carried out by T-lymphocytes and their products, lymphokines, with the help of monokines secreted by the cells of the mononuclear phagocytic system, namely, monocytes and macrophages. The lymphokines and monokines are grouped together as cytokines. Some cytokines are produced as an integral part of the immune response and are antigen specific, while others, although induced by the presence of an antigen, are antigen non-specific in function.</p>
                            <p>Depending on the role in the immune response, cytokines are classified into two groups.</p>
                            <p>Afferent cytokines have a role in the induction of primary immune responses. Efferent cytokines play a part in the suppression of immune responses.</p>

                            <h4>Afferent cytokines</h4>
                            <div class="collapsible-section">
                                <details open>
                                    <summary class="collapsible-trigger">
                                        <span class="trigger-icon">‚ñ∂</span>
                                        <span class="trigger-text"><strong>(i) Interleukin-1 (IL-1)</strong></span>
                                    </summary>
                                    <div class="collapsible-content">
                                        <p>IL-1 is primarily produced by the cells of mononuclear phagocytic system (MPS), and also by T- and B-cells, natural killer (NK) cells and many other nucleated cells. The secretion of IL-1 is generally induced by antigen, injury, toxins or inflammation, and is considered to be a primary mediator of acute phase reactions.</p>
                                        <p><strong>Functions of IL-1</strong></p>
                                        <p>(a) Activation of resting T-cells It activates resting T-cells and stimulates production of lymphokines such as Interleukin-2.</p>
                                        <p>(b) Chemotaxis: It causes chemotaxis and increased metabolism in phagocytes.</p>
                                    </div>
                                </details>
                            </div>

                            <div class="collapsible-section">
                                <details>
                                    <summary class="collapsible-trigger">
                                        <span class="trigger-icon">‚ñ∂</span>
                                        <span class="trigger-text"><strong>(ii) Interleukin-2 (IL-2)</strong></span>
                                    </summary>
                                    <div class="collapsible-content">
                                        <p>IL-2 is also known as T-cell growth factor (TCGF). It is a lymphokine produced by T-helper cells activated by IL-1. Activated T-cells produce IL-2, and at the same time receptors for IL-2 appear on their surface. (Fig. 3.1).</p>
                                        <p><strong>Functions of IL-2</strong></p>
                                        <p>(a) Proliferation of Th cells When IL-2 interacts with the IL-2 receptor on the surface of T-helper (Th) cell, it results in proliferation of Th cells, which in turn, amplify the immune response. The activated T-cells subsequently produce other interleukins (IL-4, IL-5, IL-6), which induce activation, proliferation and differentiation of B-cells.</p>
                                        <p>(b) Enhancement of killer cell activities IL-2 rapidly enhances natural killer (NK) cell activity. It increases specific killing ability of cytotoxic lymphocytes in the presence of antigen. It also acts on null (non-T, Non-B) cells which are then capable of lysing NK-resistant tumour cells.</p>
                                    </div>
                                </details>
                            </div>

                            <div class="collapsible-section">
                                <details>
                                    <summary class="collapsible-trigger">
                                        <span class="trigger-icon">‚ñ∂</span>
                                        <span class="trigger-text"><strong>(iii) Interleukin-3 (IL-3)</strong></span>
                                    </summary>
                                    <div class="collapsible-content">
                                        <p>Interleukin-3 (IL-3) or Colony stimulating Factors (multi-CSF). Colony Stimulating Factors (CSFs) are known to induce differentiation and proliferation of pleuripotent haematopoietic stem cells in vitro. IL-3 is produced by activated T-cells and perhaps by the bone marrow.</p>
                                        <p><strong>Function of IL-3</strong></p>
                                        <p>IL-3 is capable of supporting proliferation and differentiation of pleuripotent stem cells of the erythroid, lymphocytic, megakaryocytic series and mast cells.</p>
                                    </div>
                                </details>
                            </div>

                            <div class="collapsible-section">
                                <details>
                                    <summary class="collapsible-trigger">
                                        <span class="trigger-icon">‚ñ∂</span>
                                        <span class="trigger-text"><strong>(iv) Interleukin-4 (IL-4)</strong></span>
                                    </summary>
                                    <div class="collapsible-content">
                                        <p>Interleukin-4 is also known as B-cell growth factor I (BCGF I). It is produced by activated T-cells. Receptors for IL-4 are found on both T- and B-lymphocytes.</p>
                                        <p><strong>Functions of IL-4</strong></p>
                                        <p>(a) IL-4 participates in B-cell activation, differentiation, proliferation, immunoglobulin secretion, and later, also in the switch in immunoglobulin class (e.g. IgM to IgG).</p>
                                        <p>(b) IL-4 promotes the growth of T-helper (Th) cells, although to a lesser extent than IL-2.</p>
                                        <p>(c) It co-stimulates mast cells along with IL-3.</p>
                                    </div>
                                </details>
                            </div>

                            <div class="collapsible-section">
                                <details>
                                    <summary class="collapsible-trigger">
                                        <span class="trigger-icon">‚ñ∂</span>
                                        <span class="trigger-text"><strong>(v) Interleukin-5 (IL-5)</strong></span>
                                    </summary>
                                    <div class="collapsible-content">
                                        <p>Interleukin-5 is alternatively known as B-cell growth factor II (BCGFII). It is also produced by activated T-cells.</p>
                                        <p><strong>Function of IL-5</strong></p>
                                        <p>IL-5 brings about final maturation of B-cells which are already proliferating, and promotes production and secretion of immunoglobulins. IL-5 cannot induce proliferation of resting B-cells.</p>
                                    </div>
                                </details>
                            </div>

                            <div class="collapsible-section">
                                <details>
                                    <summary class="collapsible-trigger">
                                        <span class="trigger-icon">‚ñ∂</span>
                                        <span class="trigger-text"><strong>(vi) Interleukin-6 (IL-6)</strong></span>
                                    </summary>
                                    <div class="collapsible-content">
                                        <p>IL-6 is also commonly known as interferon Œ≤2 (IFNŒ≤2). IL-6 is primarily produced by fibroblasts.</p>
                                        <p><strong>Function of IL-6</strong></p>
                                        <p>IL-6 induces secretion of immunoglobulins within individual cells.</p>
                                    </div>
                                </details>
                            </div>

                            <div class="collapsible-section">
                                <details>
                                    <summary class="collapsible-trigger">
                                        <span class="trigger-icon">‚ñ∂</span>
                                        <span class="trigger-text"><strong>(vii) Interferon (IFN)</strong></span>
                                    </summary>
                                    <div class="collapsible-content">
                                        <p>Interferons is a group of cytokines that show antiviral and immunoregulatory activity. There are three main types of interferons.</p>
                                        <p>Alpha interferon (IFNŒ±) is produced primarily by leukocytes. Beta interferon (IFNŒ≤) is produced by fibroblasts and Gamma interferon (IFNŒ≥) by immune cells, mainly stimulated lymphocytes. T-helper (Th) cells, T-suppressor (Ts) cells and natural killer (NK) cells.</p>
                                        <p>IFNŒ± and IFNŒ≤ are structurally related polypeptides and have anti-viral activity and anti-proliferative and immunoregulatory activities against immune cells. IFNŒ± and IFNŒ≤‚Äîtogether with IL-2 enhance NK cell activity.</p>
                                        <p>IFNŒ≥ is mainly immunoregulatory in function. It can enhance or suppress immune response depending upon dosage and timing. IFNŒ≥ also inhibits growth of normal and neoplastic cells, and can either stimulate or inhibit haematopoiesis.</p>
                                    </div>
                                </details>
                            </div>

                            <h4>Efferent cytokines</h4>
                            <p>(i) Soluble immune response suppressors (SIRS) These are immunosuppressive cytokines produced by T-suppressor (Ts) cells. When SIRS are oxidized by hydrogen peroxide from the macrophage, macrophage function is suppressed by inhibition of cell division and immune responses.</p>
                            <p>(ii) Immunoglobulin binding factors Immunoglobulin binding factors inhibit <em>in vitro</em> antibody production.</p>
                            <p>(iii) DNA synthesis inhibitors These inhibitors bind to DNA polymerase to arrest synthesis of DNA.</p>
                            <p>(iv) Lymphotoxins Lymphotoxins are a group of proteins produced by activated T-cells. They act as efferent cytokines by exerting cytostatic and cytolytic effects on transformed cells.</p>
                            <p>(v) Cytokines acting on macrophages</p>
                            <p>(a) Macrophage migration inhibition factor (MIF) prevents the movement of macrophages.</p>
                            <p>(b) Macrophage activating factor (MAF) enhances the bactericidal and tumouricidal activity of macrophages.</p>
                            <p>(c) Macrophage chemotactic factors have affinity for macrophages.</p>
                            <p>(vi) Cytokines acting on leukocytes</p>
                            <p>(a) Leukocyte inhibition factor inhibits random and directional movement of neutrophils.</p>
                            <p>(b) PMN activating factor and eosinophil activating factor stimulate neutrophils and eosinophils respectively.</p>
                            <p>(vii) Other cytokines</p>
                            <p>Fibroblast activating factor induces wound healing and fibrosis. Efferent monokines include, among others, chemotoxins, prostaglandins, and plasminogen activator.</p>
                        </div>
                    </section>

                    <!-- Section 4: Mechanism of CMI -->
                    <section class="content-section" id="mechanism-cmi">
                        <div class="section-header">
                            <div class="section-number">04</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚öôÔ∏è</span>
                                Mechanism of Cell Mediated Immunity
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Cell mediated immunity (CMI) provides a specific immune response against infectious organisms. It also plays a role in tumour immunity, rejection of foreign grafts and delayed type hypersensitivity reactions. Cytotoxic killer cells (Tcx) are the principal effectors of CMI, except in delayed hypersensitivity reactions. When activated, they bring about the lysis of target cells such as virus infected cells, tumour cells or graft tissue.</p>
                            <p>The initiation of the immune response is the same as that for T-cell dependent activation of B-lymphocytes for the antibody mediated immune response.</p>
                            <p>Steps (i) to (v) of the mechanism of antibody mediated immunity are common to both AMI and CMI. Other steps in the mechanism of CMI are as follows:</p>
                            
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(vi) Maturation of Tcx The IL-2 produced by activated Th leads to maturation of Tcx precursor.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(vii) Direct contact between Tcx and target cell Contact occurs between antigen specific T-cell receptor (TcR) on Tcx surface membrane and the appropriate antigen on the target cell, resulting in the binding of the two cells. This binding is strengthened by simultaneous binding between the CD8 molecule on the Tcx surface membrane and a Class I HLA molecule on the target cell surface.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(viii) Cytolysis When bound to the target cell, Tcx is stimulated to produce cytolytic proteins from its cytoplasmic granules into the environment of the target cell. These proteins bring about target cell lysis by producing pores in its cell membrane. This alters the cell permeability causing osmotic swelling and lysis.</span></li>
                            </ol>

                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../assets/images/image-20251219-1fa23648.jpeg" alt="Mechanism of cell mediated immunity (CMI)" class="figure-image">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Fig. 3.3 Mechanism of cell mediated immunity (CMI)</figcaption>
                            </figure>
                        </div>
                    </section>

                    <!-- Section 5: Regulation & Immunotolerance -->
                    <section class="content-section" id="regulation">
                        <div class="section-header">
                            <div class="section-number">05</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚öñÔ∏è</span>
                                Regulation of Immunity
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>The adaptive immune responses must be 'switched on' as a result of an antigenic stimulus and switched off when they are no longer required, so that a balance between help and suppression is achieved. The regulation of the immune system is achieved through a variety of mechanisms, such as:</p>
                            
                            <p><strong>T-helper (Th) and T-suppressor (Ts) cells</strong> These two types of cells act as a check and balance system for each other. Their functions are regulated by a complex network of cellular interactions and soluble mediators.</p>
                            
                            <p><strong>Cytokines</strong> These soluble products, secreted by cells such as lymphocytes, macrophages, neutrophils, and NK cells, have both positive and negative effects on the immune response. Afferent cytokines such as interleukins, interferons and B-cell stimulating factors help in building up the immune response whereas efferent cytokines, such as macrophages inhibition factor (MIF), leukocyte inhibition factor and lymphotoxins help in the suppression of the immune response.</p>
                            
                            <p><strong>Anti-idiotypic antibodies</strong> Idiotypes are unique amino acid sequences in the variable regions of the heavy and light chains of immunoglobulins which contribute directly to the antigen binding specificity of another antibody molecule (anti-idiotypes). Activation of the immune response may also result in the production of antibodies to the idiotype portion of the newly formed antibody molecules. These anti-idiotype antibodies may bind to the surface receptors on B-cells or to TcR on T-cells. Depending on the structure of anti-idiotypes, their attachment may have one of two consequences, namely:</p>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(a) Inhibition of the immune response by blocking the attachment of antigen to these receptors, or</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(b) Enhancement of the immune response by producing the same effect as bound antigen.</span></li>
                            </ol>

                            <h3>Immunotolerance</h3>
                            <p>Immunotolerance or immunological unresponsiveness is the condition in which contact with an antigen specifically destroys the capacity of the immune system to mount an immune response against that particular antigen. This tolerance is specific for that antigen only, the response to other antigens is unaffected. Immunotolerance is very undesirable in most infections, but is very useful in the case of an organ or tissue transplant.</p>
                            
                            <p>The induction of immunotolerance depends on the following factors:</p>
                            <p><strong>Immunological maturity of the host</strong> Immunological unresponsiveness of the host to the ‚Äòself‚Äô antigens is due to the contact of immature immunological system with these antigens during embryonic life. Similarly, any antigen which comes in contact with the immune system during embryonic life would be identified as the ‚Äòself‚Äô antigen and would not induce any immune response. For this reason, if animals of one strain are injected with the cells from a second strain <em>in utero</em>, the injected animal will accept these cells as self antigens. Another example of this type of immunotolerance is the vertical transmission of some tumour viruses from mother to foetus. The viruses multiply in the foetus and continue to persist after birth, without inducing any immune response as they are recognised as self-antigens.</p>
                            <p><strong>Physical state and dose of the antigen</strong> Tolerance, instead of immune response, can be induced if very low or very high doses of an antigen are administered. Intravenous injection of huge doses may lead to immune paralysis. The immune response may revive when most of the antigen is degraded or excreted.</p>
                            <p>The physical state of the antigen is also significant. Generally, soluble antigens and haptens are more likely to lead to immunotolerance than particulate antigens. Tolerance to an antigen may end spontaneously or by administration of a cross reacting antigen.</p>
                        </div>
                    </section>

                    <!-- Section 6: Harmful Effects -->
                    <section class="content-section" id="harmful-effects">
                        <div class="section-header">
                            <div class="section-number">06</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚ö†Ô∏è</span>
                                Harmful Effects of Immunity
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Immune response may sometimes have an undesirable effect on the host. These harmful effects of immunity are:</p>
                            <p>I. Hypersensitivity reactions.<br>II. Autoimmunity.<br>III. Transplantation immunity.</p>

                            <h3>Hypersensitivity Reactions</h3>
                            <p>Hypersensitivity reactions are characterised by an altered state of immune responsiveness. Allergy is a commonly used synonym for hypersensitivity, and the antigen which causes allergy is called allergen. For hypersensitivity to occur, the host must receive an initial or sensitizing dose of the allergen. Subsequent contact with the same or related antigen, the shocking dose, results in the hypersensitivity reaction.</p>
                            <p>Hypersensitivity reactions are basically divided into two groups:</p>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">1. Antibody mediated or immediate type reactions and</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">2. Cell mediated, delayed type reactions.</span></li>
                            </ol>
                            
                            <div class="table-wrapper">
                                <div class="table-header">
                                    <span class="table-icon">üìä</span>
                                    <span class="table-title">Table 3.1: Differences between Antibody-Mediated and Cell-Mediated Reactions</span>
                                </div>
                                <div class="table-container">
                                    <table class="content-table content-table--comparison">
                                        <thead>
                                            <tr>
                                                <th>Characteristic</th>
                                                <th>Ab-Mediated or Immediate Type</th>
                                                <th>Cell-Mediated or Delayed Type</th>
                                            </tr>
                                        </thead>
                                        <tbody>
                                            <tr>
                                                <td>Clinical examples</td>
                                                <td>Anaphylactic shock; allergy to pollen with asthma; serum sickness; some allergies to antibiotics; asthmatic reaction</td>
                                                <td>Tuberculin hypersensitivity; allergy to fungi (Histopalsma), parasites (Trichinella), Rhus plants (poison ivy or oak), chemicals (nickel); skin graft rejection.</td>
                                            </tr>
                                            <tr>
                                                <td>Timing</td>
                                                <td>The reaction begins immediately, i.e. within minutes after contact with the allergen, and disappears within 1 hour</td>
                                                <td>The reaction is delayed. It begins several hours after contact with the allergen and may last for days.</td>
                                            </tr>
                                            <tr>
                                                <td>Histology</td>
                                                <td>The main pathological reaction consists of dilation of capillaries and arterioles, erythema and oedema and only limited polymorphonuclear leukocyte infiltration</td>
                                                <td>The main pathological reaction consists of inflammatory change with predominant mononuclear cell infiltration and tissue induration.</td>
                                            </tr>
                                            <tr>
                                                <td>Passive transfer</td>
                                                <td>The reaction is associated with circulating antibodies and can be transferred passively by means of serum</td>
                                                <td>The reaction is not associated with circulating antibodies and cannot be transferred passively by means of serum. It can often be transferred passively by means of lymphoid cells or their extracts.</td>
                                            </tr>
                                        </tbody>
                                    </table>
                                </div>
                            </div>

                            <p>The basic mechanisms underlying hyper-sensitivity reactions are designed for host defense. However, direction of these mechanisms towards an inappropriate antigen or chronic activation of the mechanisms can lead to pathological consequences. On the basis of pathogenesis, hypersensitivity reactions have been classified into four major types by Gell and Coombs. Out of these, types I, II and III are antibody mediated. These are manifested within a few minutes to a few hours after exposure to the inducing antigen. Type IV hypersensitivity, on the other hand, is cell mediated. This is observed 24 to 48 hours after exposure to the antigen.</p>

                            <h4>Type I Hypersensitivity: Anaphylactic shock</h4>
                            <p><strong>Mechanism</strong></p>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(i) The inducing antigen, allergen, induces the production of specific IgE antibody.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(ii) The specific IgE binds to Fc receptors on mast cells and basophils.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iii) On subsequent exposure, the allergen binds to the cell-bound IgE molecules, causing cross linking of the IgE receptors.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iv) Granules within the mast cells and basophils are released to discharge chemical mediators like histamine, leukotrienes, bradykinin etc.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(v) Chemical mediators act on various tissues leading to increased permeability of blood vessels, increased smooth muscle contractions and increased mucous secretions.</span></li>
                            </ol>
                            <p><strong>Atopy:</strong> Some type I hypersensitivity are inherited and run in families. Such a hypersensitivity is called atopy. The allergens commonly involved in atopy are characteristically inhalants, such as pollen or house dust, or ingestants such as eggs. Hay fever and asthma are typical examples.</p>

                            <h4>Type II Hypersensitivity: Cytotoxic Reaction</h4>
                            <p>Type II reactions are intermediate between hypersensitivity and autoimmunity.</p>
                            <p><strong>Mechanism</strong></p>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(i) The inducing antigen stimulates the production of IgM and IgG antibodies.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(ii) The production of antibodies may lead to:
                                    <br>(a) Agglutination of antigen particles.
                                    <br>(b) Opsonisation and subsequent phagocytosis of the antigen.
                                    <br>(c) Binding of complement to the antigen antibody complex resulting in lysis of antigen.
                                    <br>(d) Antibody dependent cellular cytotoxicity (ADCC).
                                </span></li>
                            </ol>
                            <p>Cytolytic reactions are significant in immunohaematology and can cause transfusion reactions, haemolytic disease of the newborn and autoimmune anaemias. Other examples are idiopathic thrombocytopenic purpura and Goodpasture‚Äôs disease.</p>

                            <h4>Type III Hypersensitivity: Immune Complex Disease</h4>
                            <p>Immune complex disease can occur when a soluble antigen combines with its antibody. The antigen-antibody complex may precipitate locally in a tissue, in and around small blood vessels or spread systemically via the blood stream. The deposition of the immune complexes at these sites causes local inflammation and massive complement activation, leading to tissue damage.</p>
                            <p><strong>Mechanism</strong></p>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(i) Antigen-antibody complexes are formed by induction of antibody mediated immunity (AMI) by antigen.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(ii) Complement is bound to the immune complexes.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iii) Activation of complement results in the release of the components of the complement cascade and manifestation of their biological activities.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iv) Immune complexes are bound to platelets forming aggregates of platelets and releasing vasoactive amines and increasing vasopermeability.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(v) Phagocytic cells (neutrophils and macrophages) are attracted to the site by chemotaxis where immune complexes are deposited.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(vi) Lysosomal enzymes are released by living and dead phagocytes, mediating destruction of the surrounding tissue.</span></li>
                            </ol>
                            <p>Arthus reaction and serum sickness are two well-known examples of immune complex disease.</p>

                            <h4>Type IV Hypersensitivity: Delayed Hypersensitivity</h4>
                            <p>The mechanism of delayed type hypersensitivity is independent of antibody and is closely associated with cell mediated immunity and activated T-lymphocytes. These hypersensitivity reactions are provoked by specific antigens, evolve slowly and involve lymphocytes, macrophages and neutrophils.</p>
                            <p><strong>Mechanism</strong></p>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(i) The antigen is processed by macrophages and presented to T-helper (Th) cells.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(ii) The macrophages release Interleukin-1 (IL-1), which activates Th which, in turn, secretes IL-2.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iii) IL-2 activates T-delayed type hypersensitivity cells (Td) and T-cytotoxic (Tcx) cells.
                                    <br>(a) Td promotes inflammatory response by releasing lymphokines which attract, activate and retain macrophages and neutrophils.
                                    <br>(b) Tcx activation leads to subsequent binding and lysis of target cells containing the surface antigen that induced the immune response.
                                </span></li>
                            </ol>
                            
                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../assets/images/image-20251219-312f5b84.jpeg" alt="Mechanisms of hypersensitivity reactions" class="figure-image">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Fig. 3.4 Mechanisms of four types of hypersensitivity reactions</figcaption>
                            </figure>
                        </div>
                    </section>

                    <!-- Section 7: Autoimmunity -->
                    <section class="content-section" id="autoimmunity">
                        <div class="section-header">
                            <div class="section-number">07</div>
                            <h2 class="section-title">
                                <span class="title-icon">üõë</span>
                                Autoimmunity
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Autoimmunity is a condition in which immune responses are directed toward self-antigens with consequent structural and functional damage to the host. These immune responses may involve both humoral immunity with production of auto-antibodies, and cell-mediated immunity.</p>
                            
                            <h3>Mechanisms of autoimmunity</h3>
                            <p>Autoimmunity may result under various conditions, some of which are listed below:</p>
                            <p><strong>Altered antigen theory</strong> Alteration in the surface antigens of the tissues or cells can occur as a result of physical, chemical or biological influences. Such altered antigens are considered as ‚Äònon-self‚Äô and an immune response is mounted against them. Mutation, infection with viruses and exposure to ultraviolet light are examples of some factors which can alter surface antigens.</p>
                            <p><strong>Cross-reactive antigen theory</strong> Some complex foreign structures may possess structural parts which are similar or related to self-antigens. This results in immunological cross-reactivity. The immune response mounted against the foreign complex antigen may also cross-react with similar self-antigen. For example, antibodies against some strains of Group A streptococci may cross-react with heart muscle, causing rheumatic heart disease.</p>
                            <p><strong>Hidden or sequestered antigen theory</strong> Some self-antigens are 'hidden' in the circulation in normal healthy individuals. Such a self-antigen may come in contact with the immune system only at a later stage in life, when it is treated as non-self. Such antigens are known as hidden or sequestered antigens. The lens tissue of the eye, spermatozoa, central nervous tissue are examples of sequestered antigens. These antigens come in contact with cells of the immune system only after organ damage, such as eye injury.</p>
                            <p><strong>Forbidden clone theory</strong> Breakdown of immunoregulatory mechanism may lead to the loss of 'tolerance'. Under such conditions, antigen presentation by cells which are not normally specialised for this role, may give rise to self reactivity. For example, Class II antigens of the HLA system which are normally only expressed on antigen presenting cells such as macrophages and B-lymphocytes, appear on the thyrocytes in thyroiditis, and on liver cells in biliary cirrhosis. They stimulate autoreactive T-cells to induce cytotoxic T-cells and B-lymphocytes to respond against them.</p>

                            <h3>Examples of autoimmune diseases</h3>
                            <p><strong>Systemic lupus erythematosus (SLE)</strong> SLE is a systemic disease which occurs mainly in women and has a strong hereditary tendency. Patients develop a variety of autoantibodies directed against the cell nuclei, intracytoplasmic constituents, immunoglobulins and some organ specific antigens. The LE cell phenomenon is observed in SLE (see Haematology section).</p>
                            <p><strong>Rheumatoid arthritis (RA)</strong> This is a chronic inflammatory disease, primarily affecting joints and surrounding tissues. The striking feature of the disease is the presence of several abnormal proteins circulating in the blood. These are a group of immunoglobulins which interact specifically with the antigenic determinants on the Fc fragment of the IgG molecules, i.e. they act as anti-antibodies to immunoglobulins. These proteins are collectively known as rheumatoid factor (RA factor).</p>
                            <p>Other examples of autoimmune diseases include myasthenia gravis, Addison's disease and pernicious anaemia</p>
                        </div>
                    </section>

                    <!-- Section 8: Transplantation & Immunodeficiency -->
                    <section class="content-section" id="transplant-immunodeficiency">
                        <div class="section-header">
                            <div class="section-number">08</div>
                            <h2 class="section-title">
                                <span class="title-icon">üè•</span>
                                Transplant Immunity & Immunodeficiency
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Transplant Immunity</h3>
                            <p>When an organ or a tissue is irreparably damaged, defective or absent, its function can be restored by organ transplant or tissue grafting. Transplants or grafts survive better only when the organ or tissue is taken from the recipient himself or from an identical twin. The grafts from other individuals of the same species or different species would be rejected. The speed and vigour with which these transplants are rejected depends on their mutual degree of foreignness. This is related to the genetic relationship between the donor and the recipient.</p>
                            
                            <p>There are four different types of transplants:</p>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Autograft</strong> An organ or tissue taken from an individual and grafted on himself.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Isograft</strong> An organ or tissue taken from one individual (donor) and grafted on genetically identical individual (recipient) e.g. identical twins or highly inbred strains of animals.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Allograft</strong> Grafts between genetically non-identical members of the same species, e.g. human donor and recipient.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Xenografts</strong> Grafts between members of different species, e.g. mouse donor and guinea-pig recipient.</span></li>
                            </ul>

                            <p>Generally, autografts and isografts are accepted because the grafts are genetically and antigenically compatible with the host-tissues. Allografts and xenografts are rejected due to genetic and antigenic incompatibility.</p>
                            <p>The main cause of incompatibility is the major histocompatibility complex (MHC) of each species, such as HLA (Human Leucocyte Antigen) system in man.</p>

                            <h4>Graft Versus Host (GVH) Reaction</h4>
                            <p>A grafted tissue may be rejected by the host due to the reaction of the host to the grafted tissue i.e. host versus graft response. On the other hand, when the graft tissue mounts an immune response against the antigens of the host, it is called graft versus host (GVH) reaction. GVH reaction can occur when the graft contains immunocompetent T-cells, the host has transplantation antigens which are absent in the graft and the graft is not rejected by the host.</p>

                            <h3>Immunodeficiency Diseases</h3>
                            <p>Deficiency in one or more components of the immune system leads to a condition known as immunodeficiency disease. Basic components involved are</p>
                            <p>(i) T-lymphocytes<br>(ii) B-lymphocytes<br>(iii) Phagocytic cells<br>(iv) Complement system.</p>
                            <p>Immunodeficiency may be primary or secondary.</p>
                            <p>Primary immunodeficiency is congenitally derived due to genetic defects. Many of these are X-linked i.e. inherited by boys from their mothers. The defect may be due to the interruption of differentiation of immunocompetent cells at some stage of development, or due to missing gene products, e.g. individual components of the complement system.</p>
                            <p>Secondary immunodeficiency is acquired as a result of other factors such as</p>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(i) Malnutrition Reduced intake of proteins, carbohydrates, and minerals such as iron and zinc can lead to defects in antibody formation or T-cell development.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(ii) Infections Many infections lead to immunosuppression. The acquired immune deficiency syndrome (AIDS) is mainly due to a viral infection of Th cells.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iii) Tumours Tumours such as Hodgkin's disease, myeloma, leukaemias etc. are often associated with immunodeficiency</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iv) Opportunistic infections Severely immunocompromised patients may develop infections with different types of 'opportunistic' organisms. These are usually organisms of low pathogenicity and can cause serious infections mainly when host's defence mechanisms are impaired. Opportunistic infections are the usual cause of death in patients with AIDS, malignancy or in recipients of organ transplants. Examples of opportunistic pathogens are:
                                    <br>- Bacteria e.g. <em>Pseudomonas aeruginosa</em>, <em>Mycobacterium tuberculosis</em>
                                    <br>- Viruses e.g. <em>Herpes simplex</em>, cytomegalovirus
                                    <br>- Fungi e.g. <em>Candida albicans</em>, <em>Histoplasma capsulatum</em>
                                    <br>- Protozoa e.g. <em>Cryptosporidium</em>, <em>Pneumocystis carinii</em>
                                </span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(v) Drugs Drugs can cause immunodeficiency either intentionally as in transplantation, hypersensitivity or autoimmunity; or unintentionally.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(vi) Age Immunity is weaker during infancy and in old age.</span></li>
                            </ol>

                            <h3>Immunoproliferative Diseases</h3>
                            <p>Malignant proliferation of one or more key cells of the immune system results in immunoproliferative diseases. These diseases include:</p>
                            <p>(i) Leukaemias involving T- or B-lymphocytes, null cells or monocytes.<br>(ii) Lymphomas involving lymphoid cells within a solid tissue.<br>(iii) Monoclonal gammopathies which are a result of proliferation of malignant plasma cells that produce large quantities of a homogeneous immunoglobulin, for example multiple myeloma.</p>
                        </div>
                    </section>

                    <!-- Key Points Section -->
                    <aside class="key-points-section" role="region" aria-labelledby="key-points-title">
                        <div class="key-points-wrapper">
                            <div class="key-points-header">
                                <span class="key-points-icon">‚≠ê</span>
                                <h3 id="key-points-title" class="key-points-title">Key Points</h3>
                            </div>
                            <ul class="key-points-list">
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Specific immune response can be either antibody mediated or cell mediated.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Each immunocompetent B-lymphocyte has an immunoglobulin of appropriately coded specificity on its surface, before its exposure to the antigen.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>When an individual is exposed to an antigen for the first time, it results in the primary antibody response.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Cell mediated immunity (CMI) provides a specific immune response against infectious organisms.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Hypersensitivity reactions are characterised by an altered state of immune responsiveness.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Autoimmunity is a condition in which immune responses are directed toward self-antigens with consequent structural and functional damage to the host.</strong></p>
                                </li>
                            </ul>
                        </div>
                    </aside>

                </main>

                <!-- BOTTOM NAVIGATION -->
                <nav class="document-nav" role="navigation" aria-label="Document Navigation">
                    <div class="nav-links">
                        <a href="topic-02-antigen-antibody.html" class="nav-button nav-button--previous">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Previous</span>
                        </a>
                        
                        <a href="../index.html" class="nav-button">
                            <span class="nav-icon">üè†</span>
                            <span class="nav-text">Home</span>
                        </a>
                        
                        <a href="topic-04-in-vitro-reactions.html" class="nav-button nav-button--next">
                            <span class="nav-text">Next</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                    <div class="document-progress">
                        <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 60%;"></div>
                        </div>
                        <span class="progress-text">Topic 3 of 5</span>
                    </div>
                </nav>

            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div id="lightbox" class="lightbox-modal" hidden aria-hidden="true" role="dialog" aria-label="Image viewer">
        <div class="lightbox-backdrop"></div>
        <div class="lightbox-content">
            <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
            <img class="lightbox-image" src="" alt="">
            <p class="lightbox-caption"></p>
        </div>
    </div>

    <!-- Scripts -->
    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>